{
  "ticker": "EBS",
  "company_name": "Emergent BioSolutions Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07268612",
      "title": "Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.",
      "status": "NOT_YET_RECRUITING",
      "phase": "",
      "condition": "Anthrax",
      "start_date": "2035-11",
      "completion_date": "2037-11",
      "enrollment": 0,
      "sponsor": "Emergent BioSolutions"
    },
    {
      "nct_id": "NCT05349617",
      "title": "Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults \u226565 Years",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chikungunya Virus",
      "start_date": "2022-05-12",
      "completion_date": "2023-08-08",
      "enrollment": 0,
      "sponsor": "Bavarian Nordic"
    },
    {
      "nct_id": "NCT01979406",
      "title": "A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Anthrax Infection",
      "start_date": "2013-11",
      "completion_date": "2015-09",
      "enrollment": 0,
      "sponsor": "Emergent BioSolutions"
    },
    {
      "nct_id": "NCT02100631",
      "title": "A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Cholera",
      "start_date": "2014-05",
      "completion_date": "2015-06",
      "enrollment": 0,
      "sponsor": "Bavarian Nordic"
    },
    {
      "nct_id": "NCT00053482",
      "title": "Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Smallpox",
      "start_date": "2003-01",
      "completion_date": "2003-10",
      "enrollment": 0,
      "sponsor": "Emergent BioSolutions"
    },
    {
      "nct_id": "NCT03483961",
      "title": "Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Chikungunya Virus Infection",
      "start_date": "2018-04-18",
      "completion_date": "2020-09-21",
      "enrollment": 0,
      "sponsor": "Bavarian Nordic"
    },
    {
      "nct_id": "NCT00679172",
      "title": "Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Typhoid",
      "start_date": "2008-05",
      "completion_date": "2008-12",
      "enrollment": 0,
      "sponsor": "Emergent BioSolutions"
    },
    {
      "nct_id": "NCT02771730",
      "title": "Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteer, HIV Vaccine",
      "start_date": "2015-03",
      "completion_date": "2017-02",
      "enrollment": 0,
      "sponsor": "Emergent BioSolutions"
    },
    {
      "nct_id": "NCT03315104",
      "title": "Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Influenza A H3N2, Influenza A H1N1",
      "start_date": "2017-11-17",
      "completion_date": "2019-06-17",
      "enrollment": 0,
      "sponsor": "Emergent BioSolutions"
    },
    {
      "nct_id": "NCT03220737",
      "title": "VAXCHORA Pediatric Study to Assess Safety and Immunogenicity",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Cholera (Disorder)",
      "start_date": "2017-07-21",
      "completion_date": "2020-03-06",
      "enrollment": 0,
      "sponsor": "Bavarian Nordic"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "": 7,
      "PHASE3": 8,
      "PHASE1": 16,
      "PHASE2": 12,
      "PHASE4": 5,
      "PHASE1, PHASE2": 1,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "NOT_YET_RECRUITING": 3,
      "COMPLETED": 40,
      "TERMINATED": 6,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 1,
    "completed_trials": 40,
    "conditions": [
      "Adenoviral Infection",
      "Anthrax",
      "Anthrax Infection",
      "Arthritis, Rheumatoid",
      "Bacillus Anthracis (Anthrax) Infection",
      "Bird Flu, Influenza",
      "Botulism",
      "Chikungunya",
      "Chikungunya Virus",
      "Chikungunya Virus Infection",
      "Cholera",
      "Cholera (Disorder)",
      "Healthy",
      "Healthy Volunteer, HIV Vaccine",
      "Healthy Volunteers",
      "Human Influenza",
      "Infections, Bacterial",
      "Influenza A H3N2, Influenza A H1N1",
      "Inhalational Anthrax",
      "Myocarditis, Pericarditis",
      "Opioid Overdose",
      "Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities",
      "SARS-CoV-2 Infection",
      "Smallpox",
      "Smallpox Vaccine Adverse Reaction",
      "Symptoms of Inhalational Anthrax",
      "T Cell Lymphoma",
      "T-cell Lymphoma",
      "Tuberculosis",
      "Typhoid",
      "Typhoid Fever",
      "Vaccine Response",
      "Viral Infection",
      "Zika Virus Infection, Zika Virus Disease"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:05.634325",
    "search_query": "Emergent BioSolutions Inc.",
    "url": "https://clinicaltrials.gov/search?term=Emergent+BioSolutions+Inc."
  }
}